ABSTRACT Objective: Down syndrome (DS) belongs to the most common causes of mental retardation in men, therefore new approaches allowing its rapid and effective prenatal detection are being explored. In our study we focused on diagnostic potential of plasma microRNAs. We follow up on our previous study in DS placentas, where seven miRNAs were found as being significantly elevated.
patients suffer from cognitive impairment of various degree and craniofacial abnormalities. Other phenotypic characters, like cardiovascular defects, childhood leukemia, gastrointestinal anomalies or early onset Alzheimer's disease, occur with various frequencies and exhibit interindividual heterogeneity [2] . It is generally accepted that the DS phenotype is caused by excess genetic material of chromosome 21 (Hsa21), however, specific molecular mechanisms or pathways clarifying particular DS features have still not been found [3] .
Many studies focused on gene expression in various DS biological samples (fetal or placental tissues, amniotic fluid cells, fetal or maternal blood, etc.) and they have come to varied results. Some of these expression studies have even concluded that Hsa21 genes in DS are not significantly more expressed than other disomic genes [4] [5] [6] .
The hypothesis that major or most serious DS manifestations are basically caused by a few genes located at relatively small region on Hsa21, so-called Down Syndrome Critical Region (DSCR), was often discussed in last years [7] [8] [9] .
Nevertheless, after reanalysis of all documented cases with partial trisomy 21 (PT21), presumed DSCR was limited to highly restricted DSCR (HR-DSCR), which does not contain any known gene, except for one novel miRNA gene [10] .
Thus, all observations suggest that DS phenotype is a consequence of global gene expression misregulation, which occurs mainly due to imbalanced interactions between trisomic and disomic genes but reflects also variability of overall individual genome [11, 12] . Greater impact is apparently exerted by haploinsufficient genes, which show recognizable phenotype after one allele loss [13] . These genes, for example dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A), are also sensitive to three copies [14, 15] . Moreover, individual genomic and epigenomic backgrounds including microRNA (miRNA) gene expression regulation probably contribute to the final DS phenotype [16] . miRNAs are small (17-25 nucleotides) non-coding RNAs, which regulate gene expression at the post-transcriptional level. In most cases, binding of miRNA to target mRNA with partial complementarity induce inhibition of translation (RNA silencing). Otherwise, when high degree of complementarity between miRNA and its target is achieved, the mRNA is degraded [17] . More than 2600 human miRNAs have been described till today [18] . However, it was found that one miRNA may affect hundreds of mRNAs, as a result, miRNAs regulate virtually all cellular processes.
Therefore, miRNAs were studied in relation to various pathologies, including cancer, cardiovascular diseases, diabetes or autoimmune diseases [19] [20] [21] [22] . Extracellular miRNAs associated with pregnancy are also systematically investigated in plasma of pregnant women. Although differential miRNAs profile was described in many pregnancy-related conditions (preeclampsia, preterm delivery, ectopic pregnancy, gestational diabetes mellitus, fetal trisomies, etc.) in comparison with normal pregnancies, specific mechanisms of miRNAs release to maternal circulation are not fully elucidated [23, 24] . While most authors presume placental origin of these miRNAs as in case of cell-free DNA, some hypotheses also suggest their possible fetal origin [25, 26] .
Presented study follows on our previous study comparing miRNA expression profiles in euploid and trisomic placentas, where seven miRNAs were found to be significantly up-regulated in DS placentas, three of these miRNAs are located on chromosome 21 [27] . As miRNAs are released via vesicles from placenta to maternal circulation we focused in the current study on plasma samples of pregnant women bearing DS or euploid fetuses to further investigate biological functions of miRNAs and to explore their potential for NIPT [28, 29] .
Methods
The study consisted of two phases. Pilot study was performed using Affymetrix GeneChip™ miRNA 4.1 Array Strips (Affymetrix, USA) and enabled us to select broader spectrum of miRNAs with different expression between compared groups (18 samples of plasma of pregnant women included; 9 with trisomic and 9 with euploid fetuses). Based on the pilot study results, our previous research on CVS samples [27] and literature, the group of 23 miRNAs were finally selected for the subsequent validation (Table 1) pathologies (e.g., preeclamspia), which can affect overall miRNA profile, were included to our study [55, 56] . There were no statistically significant differences between compared groups of samples in maternal age, BMI, fetal sex or samples storage time (Table 3 ).
The study was approved by the Ethical Committee of the First Faculty of Medicine, Charles University and General University Hospital in Prague. The informed consents were obtained from all participants. Table 3 Sample processing and miRNA isolation Plasma separation and storage Peripheral blood samples were collected by venipuncture using cell-free DNA BCT tubes (Streck, USA) to prevent coagulation. Tubes were stored at room temperature and processed within 6 hours after sampling at the Institute of Biology and Medical Genetics of the First Faculty of Medicine and General University Hospital in Prague and Genvia Genetic Laboratories. Two-step centrifugation was performed to obtain plasma samples from peripheral blood samples: 1) 1100g/10min at 10˚C and 2) 14500g/10min at room temperature. Plasma samples were finally frozen to -80˚C.
Optimization of the miRNA extraction
In an effort to achieve the highest miRNA yield, we tested 6 different miRNA isolation kits -NucleoSpin miRNA Plasma (Macherey-Nagel, Germany), miRCURY RNA as measured with spectrophotometer were about ten times higher (20-30ng/μl).
Pilot study -genome-wide miRNA profiling
Total RNA (130ng) enriched for low molecular weight RNA from each sample was labelled using FlashTag Biotin HSR RNA Labelling Kit (Affymetrix) on GeneAtlas Hybridization Station (Affymetrix) and subsequently it was processed using GeneAtlas Hybridization, Wash and Stain Kit for miRNA Array Strips (Applied Biosystems) on GeneAtlas Fluidics Station (Affymetrix) according to the manufacturer's instructions. Array strip fluorescence intensities were finally determined using GeneAtlas Imaging Station (Affymetrix). Raw data were processed and visualized using Partek Genomics Suite software (Partek, USA).
Selection of the miRNA set for the validation study
A total of 23 miRNAs were selected for the validation study (Table 1 ). The set of miRNAs consisted of three groups: 1) seven miRNAs verified as being overexpressed in DS placentas in our previous study [27] 2) 12 miRNAs with significantly different expression levels between euploid and DS plasma samples of pregnant women according to the results of the pilot study (pvalue ≤ 0.05; fold change ≥ 1.5)
3) four miRNAs which did not fulfil the above conditions but were reported in the literature as being possibly associated with Down syndrome pathophysiology [26, 30, 31] .
Validation study
The same total miRNAs input (4ng) from each sample based on fluorometer (Qubit 3.0) measurement was reverse-transcribed using TaqMan™ Advanced miRNA cDNA Synthesis Kit (Applied Biosystems). Expression of each miRNA was consequently determined using quantitative real-time PCR (qPCR) with TaqMan Advanced miRNA Assays and TaqMan Fast Advanced Master Mix (Applied Biosystems). We have followed the procedure recommended by the manufacturer. All reactions were performed in triplicate. miRNAs' expression levels were detected on QuantStudio 12K Flex Real-time PCR System (Applied Biosystems).
Data analysis

Pilot study
Raw results of miRNA array strips were evaluated using Partek Genomics Suite software (Partek, USA). One-way ANOVA with a cut-off p-value ≤ 0.05 and fold change (FC) ≥ 1.5 was used for detection of differentially expressed miRNAs. To control the false discovery rate, the Benjamini-Hochberg correction was applied. All visualisations, such as heatmaps, were prepared using Partek software as well.
Samples were normalized with the same miRNAs input volume. 
Results
Pilot study
Initial study phase served to identify a wider panel of potentially deregulated miRNAs in plasma of pregnant women with DS fetuses. Thus, the genome-wide analysis, which allows detect expression of all miRNAs listed in mirBase v.20 in one reaction, was selected. A total of 18 plasma samples (9 with fetal trisomy 21; 9 with normal karyotype) were loaded into Affymetrix miRNA array strips in the pilot study.
Clear separation of compared groups of samples based on principal component analysis (PCA) is visualised on Figure 1 .
Twelve miRNAs which most significantly discriminated the two compared groups of samples were selected using one-way ANOVA (p-value ≤ 0.05; FC ≥ 1.5; Table 1 ).
Half of these miRNAs were up-regulated in samples with fetal trisomy, half of them were down-regulated. None of 12 selected miRNAs are on the chromosome 21.
Seven miRNAs that were validated as significantly elevated in DS placentas in our previous study [27] were not among the differentially expressed miRNAs in the current pilot study with plasma samples. 
Validation study
Finally, a total of 23 miRNAs were selected for the validation study (Table 1) . Apart from the 12 miRNAs identified in the abovementioned pilot study, the selection was based on the results of our previous study focused on placenta samples (7 miRNA) and the results of current pilot study in combination with information in literature (4 miRNAs) [26, [30] [31] [32] [33] .
The expressions of 23 selected miRNAs were determined using qPCR analysis with individual miRNA assays in an independent set of samples. A total of 52 plasma samples (26 with fetal trisomy 21; 26 with normal karyotype) were included.
Differences in miRNA levels between compared groups of samples were evaluated using non-parametric Mann-Whitney U-test (p-value ≤ 0.05; FC ≥ 2; BenjaminiHochberg correction). None of the 23 tested miRNAs was confirmed to be significantly differentially expressed between plasma samples with fetal trisomy and samples with confirmed normal karyotype of the fetuses. Table 1 Discussion
In our previous research we performed miRNA expression profiling of CVS samples from euploid and trisomic pregnancies [27] . A total of 80 CVS samples (40 with normal karyotype, 40 with trisomy of chromosome 21) were included. Seven miRNAs were finally verified using qPCR as significantly up-regulated in DS placentas (miR99a, miR-542-5p, miR-10b, miR-125b, miR-615, let-7c and miR-654), three of them were located on chromosome 21 (miR-99a, miR-125b, let-7c). Except for various essential biological processes, we identified many genes involved in placenta development (GJA1, CDH11, EGF, ERVW-1, ERVFRD-1, LEP or INHA) as being potentially altered by elevated miRNA levels.
It was found that human placenta expresses more than 500 different miRNAs, some of them specific for this tissue [34] . Placental-specific miRNAs are expressed from three main clusters -C14MC (chromosome 14 miRNA cluster), C19MC and miR-371-3 [35] . Typical changes in expression of miRNAs from these three clusters during pregnancy suggest their potential involvement in physiological processes [36] . For example, expression of miRNAs from cluster C19MC increases continually from first to third trimester and closely correlates with placenta growth [37] . miRNAs are released from placenta, primarily from placental trophoblast, into maternal and fetal circulation mainly via exosomes [28] . However, placenta is not the only determinant of pregnancy-associated miRNA levels in maternal and fetal blood, another source or mechanism influencing these levels is probably involved [29] .
Hypothesis that miRNAs are somehow transported from fetus into the maternal circulation and vice versa is still unproven [26] .
To further extend our knowledge about biological functions of miRNAs and assess their diagnostic potential, we focused in the follow-up study on maternal plasma samples. To our best knowledge, this is the first study performing genome-wide miRNA profiling in plasma samples of pregnant women with euploid and DS fetuses. impossible to analyze cell-free nucleic acids from placenta [32] .
To achieve the highest yield and purity of miRNAs from plasma for the purposes of Affymetrix miRNA array strips we performed exhaustive and systematic method optimization (Materials and Methods; S1). Utilization of miRNA arrays enabled us to evaluate all miRNAs listed in miRBase v.20 in one reaction. Twelve miRNAs were identified as being significantly dysregulated between compared groups of samples.
Nevertheless, promising results from the initial study phase were not verified in subsequent validation phase using more sensitive method RT-PCR and larger group of samples.
We could not select a single miRNA that would discriminate euploid and DS pregnancies on the plasma level. However, clear separation of compared groups is visible when comparing the levels of the larger group of most dysregulated miRNAs obtained from miRNA arrays (Figure 2 ).
Several articles comparing miRNA levels in plasma of pregnant women bearing euploid and DS fetuses have been published so far (Table 2) . Nevertheless, these studies may have possibly come to different results due to different workflow used.
The lack of a standardized normalization strategy represents a general issue in case of plasma miRNAs evaluation. Various reference miRNAs are used for normalization of raw expression data. For example, miR-16 is often selected as a reference target, but it was found to be very susceptible to hemolysis [38] . Small nuclear or nucleolar RNAs are suitable only for normalization of samples where nuclear material is expected, but not for plasma samples [39] . On the other hand, global mean normalization is applicable only for larger miRNA set (>100 miRNAs) [40] . To prevent distortion of our results, we decided to normalize our data with the same total miRNAs input as described previously [41] . (miR-99a, let-7c, miR-125b-2, miR-155 and miR-802) using qPCR with normalization to reference miRNAs -miR-16 and let-7d [42] . Nevertheless, they found no differences between selected miRNA levels in compared groups of samples (12 pregnancies with DS fetuses; 12 control samples). Another study evaluating 14 miRNAs from Hsa21 (including five miRNAs which Kotlabova et al. focused on) also using qPCR with normalization to U6 snRNA was published by Erturk et al. [24] . They compared 33 euploid and 23 trisomic pregnancies and found two miRNAs -miR-99a and miR-3156, which were elevated in DS pregnancies. The most comprehensive study so far has been carried out by Kamhieh-Milz et al. [26] . A group of 1043 miRNAs were analyzed using high-throughput qPCR SmartChip Human miRNA Panel, nevertheless, a very small number of samples were included (7 DS fetuses; 7 controls). Using combination of three different normalization strategies (corrected threshold cycle values, normalized relative quantities and combination of both methods together) they found 36 miRNAs to be differentially expressed in DS versus control pregnancies, neither miR-99a nor miR-3156 were among them. The latest work on the topic was published by Zbucka-Kretowska et al. [43] . They examined levels of 800 miRNAs using NanoString technology within 12 DS pregnancies and 12 controls. Using normalization to geometric mean of top 100 probes (global mean), the group of 13 miRNAs was found to be deregulated. Table 2 Except the study of Kotlabova, remaining three studies apparently did not apply any correction for multiple testing. Omitting this correction can lead to a false positive results, especially in the case of a high number of comparisons and small sample size, as in case of Kamhieh-Milz or Zbucka-Kretowska studies [44] . Moreover, Zbucka-Kretowska et al. themselves reported that using Benjamini-Hochberg's correction they would not reach any statistically significant results.
Our study included samples from early gestational weeks (11 th -14 th ), which would allow potential utilization of miRNA markers found for early NIPT. However, our results from the validation study demonstrate, that levels of pregnancy associated miRNAs are apparently too low in such early pregnancies. Analysis of samples from later gestational weeks would potentially lead to different results, but without required potential for early diagnosis. Differences in gestational age could also contribute to the discrepancies between results of studies compared ( Table 2) .
Next to the different detection platforms, various preanalytical steps in sample handling, like sample storage conditions (time, temperature), type of preservative tube, concrete blood centrifugation conditions for plasma separation, plasma input volume to isolation or type of miRNA isolation (see supplement materials; S1), have also proven impact on the results achieved [38, 45, 46] .
Regardless of different procedures and data processing, none of the studies comparing plasma samples from euploid and DS pregnancies found any miRNA, which could discriminate compared groups in all cases. So, it seems that miRNAs determination in plasma of pregnant women is not applicable for NIPT of fetal DS.
Since most of placental miRNAs are released to the circulation of pregnant woman via exosomes [28] , it would be interesting in the future study to focus specifically on exosomal miRNAs. Exosomal miRNAs may be overlapped in the pool of total plasmatic miRNAs by other abundant miRNAs associated with RNA-binding proteins or derived from apoptotic cells. Exosomes are specific subtype of extracellular vesicles, which probably play a significant role in intercellular communication pathways involved in placentation, formation of vascular system between the mother and fetus or inducing of maternal immune tolerance to the fetus [47] [48] [49] [50] .
Therefore, exosomes could have potential as early non-invasive biomarkers of various pregnancy complications especially connected to placenta development.
Indeed, exosomes are currently intensively studied in relation to preeclampsia [51, 52] . As Down syndrome pregnancies are also complicated by abnormal placentation [53] , exosomes released from such an impaired placenta could be also promising markers for early detection of Down syndrome fetuses from maternal circulation. So far, miRNAs from circulating nanoparticles have only been studied in young individuals with DS and their siblings with promising results achieved [54] .
Conclusions
Previously, we found dysregulated miRNA levels in DS placentas that potentially interfere with essential biological pathways. In our current study, we focused on plasma of pregnant women to explore whether overexpressed placental miRNAs are also detectable in maternal circulation and therefore applicable for NIPT. To our best knowledge, this is the first study performing genome-wide profiling of plasmatic miRNAs on such a large cohort of first trimester pregnant women with DS fetuses. However, we could not conclusively demonstrate differences in miRNA levels in the first trimester plasma of pregnant women with euploid and DS fetuses.
The main reason probably was the high background of maternal miRNAs, which did not allow detection of potential differences in pregnancy-associated miRNAs at such early pregnancies. Nevertheless, further research will be needed to clarify the role of miRNAs in DS pathophysiology.
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